CohBar, Inc. Continues Exploration of Mitochondrial Genome and Expansion of Its IP Portfolio with Filing of 29 New Provisional Patents
MENLO PARK, Calif.--(BUSINESS WIRE)-- CohBar, Inc. (OTCQX: CWBR and TSXV: COB.U), a preclinical stage biotechnology company focused on developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced the discovery of a number of new biologically active peptides encoded within the mitochondrial genome and the filing of 29 additional related provisional patent applications. The provisional patent applications also cover novel analogs developed by CohBar that are based on the biologically active peptides. During 2016, the Company filed over 50 provisional patents related to its mitochondrial peptide discoveries and novel analogs.
“Our ongoing exploration of the mitochondrial genome continues to identify new peptides with potential for metabolic regulation and protection,” stated CohBar’s CEO Simon Allen. “We believe that the new biologically active peptides we’ve discovered to date help advance the development of drug candidates to address the metabolic dysfunction underlying age-related diseases. Our related provisional patent filings support our strategy to establish and secure a leading intellectual property position in mitochondrial peptides, as we continue to evaluate these compounds and their analogs for possible addition to our clinical development pipeline.”
About the Mitochondrial Genome and CohBar’s MBTs
Mitochondria,
the only parts of the cell other than the nucleus that have their own
genome, produce energy and regulate cell death in response to signals
received from the cell. Until recently, scientists believed the
mitochondrial genome contained a limited number of genes and, as a
result, it had been relatively unexplored as a focus of drug discovery
efforts. Research by CohBar founders and their academic collaborators
revealed that the mitochondrial genome contains significantly more
potential new genes that encode various peptides. In preclinical models
of age-related diseases, a number of these mitochondrial-derived
peptides (MDPs) have shown potential disease-modifying effects including
metabolic regulation, neuro-protective, cyto-protective and
anti-inflammatory activity. CohBar’s proprietary platform technology
involves exploring the mitochondrial genome for new peptides that
exhibit biological activity, and optimizing their structures using cell
based and preclinical models to develop proprietary MBTs with the
potential to treat a range of age-related diseases. To date, the Company
and its founders have discovered more than 50 biologically active
mitochondrial peptides.
About CohBar’s Clinical Development Program
CohBar’s lead
clinical development program is based on MOTS-c, an MDP discovered in
2012 by the Company’s founders and their academic collaborators, whose
research has shown that MOTS-c plays a significant role in the
regulation of metabolism. The Company has developed optimized analogs of
the MOTS-c peptide and identified two of these analogs, CB42009 and
CB4211, as drug candidates for advancement into IND-enabling activities.
The drug candidates have demonstrated significant therapeutic potential
in preclinical models for the treatment of obesity, with additional
ongoing studies to determine their therapeutic potential for the
treatment of nonalcoholic steatohepatitis (NASH), an advanced form of
fatty liver disease, and as an add-on to other drugs for the treatment
of Type-2 diabetes.
About CohBar
CohBar (OTCQX: CWBR and TSXV: COB.U) is a
preclinical stage biotechnology company focused on the research and
development of mitochondria based therapeutics (MBTs), an emerging class
of drugs for the treatment of age-related diseases. MBTs originate from
the discovery of a novel group of peptides within the mitochondrial
genome, which regulate metabolism and cell death and whose biological
activity declines with age. CohBar’s efforts focus on the development of
mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that
offer the potential to address a broad range of age-related diseases,
including obesity, fatty liver disease, Type-2 diabetes, and some types
of cancer and neurodegenerative disorders.
For additional company information, please visit www.cohbar.com.
Forward-Looking Statements
This news release contains
forward-looking statements, including: statements concerning CohBar’s
plans, prospects, resources and capabilities, including statements
regarding its research and development activities, expectations
regarding the therapeutic potential of mitochondrial-derived peptides,
potential for additional discoveries, and expectations regarding future
development of our intellectual property portfolio. Forward-looking
statements are based on current expectations, estimates and projections
that involve a number of risks and uncertainties that could cause actual
results to differ materially from those anticipated by CohBar. These
risks and uncertainties include the possibility of unfavorable research
results and CohBar’s ability to obtain capital, retain key personnel,
expand its research operations, and successfully advance its drug
discovery and development programs. Additional assumptions, risks and
uncertainties are described in detail in our registration statements,
reports and other filings with the Securities and Exchange Commission
and applicable Canadian securities regulators, which are available on
our website, and at www.sec.gov or www.sedar.com.
You are cautioned that such statements are not guarantees of future
performance and that our actual results may differ materially from those
set forth in the forward-looking statements. The forward-looking
statements and other information contained in this news release are made
as of the date hereof and CohBar does not undertake any obligation to
update publicly or revise any forward-looking statements or information,
whether as a result of new information, future events or otherwise,
unless so required by applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161206005450/en/
CohBar, Inc.
Anna Schram, 650-446-7888 xt 114
Investor
Relations
anna.schram@cohbar.com
Source: CohBar, Inc.
Released December 6, 2016